We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

7 hedge funds and large institutions have $845K invested in Alexion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 693 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

99% less funds holding

Funds holding: 707 → 7 (-700)

100% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 693

100% less funds holding in top 10

Funds holding in top 10: 77 → 0 (-77)

100% less capital invested

Capital invested by funds: $38.8B → $845K (-$38.8B)

Holders
7
Holders Change
-700
Holders Change %
-99.01%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
-77
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
693
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NICM
Neo Ivy Capital Management
New York
+$475K
2
TAIM
TD Ameritrade Investment Management
Nebraska
+$131K
3
RG
Retirement Group
California
+$9.37K

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$3.74B
2
BlackRock
BlackRock
New York
-$3.21B
3
State Street
State Street
Massachusetts
-$1.84B
4
FCM
Farallon Capital Management
California
-$1.42B
5
HI
HBK Investments
Texas
-$1.21B
Name Holding Trade Value Shares
Change 		Change in
Stake
BCI
1
Brinker Capital Investments
Pennsylvania
$423K – – –
NICM
2
Neo Ivy Capital Management
New York
$290K +$475K +2,587 New
TAIM
3
TD Ameritrade Investment Management
Nebraska
$85K +$131K +714 +2,644%
Barclays
4
Barclays
United Kingdom
$22K -$450M -2,449,972 -100%
RG
5
Retirement Group
California
$13K +$9.37K +51 +567%
CFO
6
CVA Family Office
Colorado
$11K -$26.6K -145 -59%
MAM
7
Meeder Asset Management
Ohio
$1K -$1.18M -6,396 -100%
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$3.74B -20,367,300 Closed
BlackRock
9
BlackRock
New York
– -$3.21B -17,495,607 Closed
State Street
10
State Street
Massachusetts
– -$1.84B -10,033,808 Closed
FCM
11
Farallon Capital Management
California
– -$1.42B -7,707,500 Closed
HI
12
HBK Investments
Texas
– -$1.21B -6,600,000 Closed
DKCM
13
Davidson Kempner Capital Management
New York
– -$1.01B -5,473,378 Closed
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
– -$962M -5,238,014 Closed
PCM
15
Pentwater Capital Management
Florida
– -$906M -4,933,200 Closed
Millennium Management
16
Millennium Management
New York
– -$887M -4,829,380 Closed
UOC
17
UBS O'Connor
Illinois
– -$813M -4,428,122 Closed
Citigroup
18
Citigroup
New York
– -$809M -4,404,598 Closed
Geode Capital Management
19
Geode Capital Management
Massachusetts
– -$760M -4,145,346 Closed
Fidelity Investments
20
Fidelity Investments
Massachusetts
– -$740M -4,029,557 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$597M -3,248,848 Closed
Renaissance Technologies
22
Renaissance Technologies
New York
– -$578M -3,147,521 Closed
Northern Trust
23
Northern Trust
Illinois
– -$512M -2,788,528 Closed
CA
24
Capitolis Advisors
New York
– -$413M -2,247,287 Closed
Deutsche Bank
25
Deutsche Bank
Germany
– -$407M -2,217,236 Closed
1
2 3 4 5

ALXN Hedge Fund Activity: Q3 2021 in Review

7 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2021, worth a combined $845K — down 100% from $38.8B a quarter earlier.

Sellers outnumbered buyers: 693 funds closed out of ALXN and 1 opened new positions — a net loss of 692 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $475K. The largest seller was Vanguard Group, exiting entirely with an estimated $3.74B sold.

  • 7 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2021, down from 707 in Q2 2021.
  • Funds reported $845K of Alexion Pharmaceuticals stock for Q3 2021, down 100% quarter-over-quarter.
  • 1 fund opened new Alexion Pharmaceuticals positions in Q3 2021 and 693 closed out, a net change of -692 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $475K added.
  • The largest Alexion Pharmaceuticals seller in Q3 2021 was Vanguard Group, an estimated $3.74B sold.

Based on aggregated 13F filings for Q3 2021.